Subcutaneous · GLP-2 receptor agonist
Apraglutide
12 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
12
Ongoing
2
Recruiting
1
Completed
8
Sites
220
Countries
26
Endpoints
251
Composite endpoints
7
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
4
Phase 1/2
3
Phase 2
2
Phase 3
3
Trials by status
Recruiting
1
Active, not recruiting
1
Completed
8
Terminated
1
Withdrawn
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
99
Other (unclassified)
93
Other clinical outcomes
35
Patient-reported / QoL
18
Cardiovascular outcomes
2
Weight & body composition
2
MASH / liver
1
Cardiometabolic biomarkers
1
Top 20 metrics across this asset's endpoints
PGI, changePRO/QoL
5
Treatment-emergent AEs (any)Safety/PK
3
All-cause deathCV
2
Immunogenicity (ADA)Safety/PK
1
Body weight, absolute change (kg)Weight
1
SF-36 totalPRO/QoL
1
EQ-5D indexPRO/QoL
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
12 of 12
Showing 1-12 of 12 trials